Mivebresib

TargetMol
Product Code: TAR-T3712
Supplier: TargetMol
CodeSizePrice
TAR-T3712-1mg1mg£113.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3712-2mg2mg£131.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3712-5mg5mg£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3712-1mL1 mL * 10 mM (in DMSO)£151.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3712-10mg10mg£201.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3712-25mg25mg£287.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3712-50mg50mg£461.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3712-100mg100mg£629.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Mivebresib, also known as ABBV-075, is a potent BET inhibitor (bromodomain (BRD)-containing protein) with potential antineoplastic activity. Upon administration, the bromodomain inhibitor ABBV-075 binds to the acetyl-lysine binding site in the BRD of certain BRD-containing protein(s), thereby preventing the interaction between those proteins and acetylated histones. This disrupts chromatin remodeling, prevents the expression of certain growth-promoting genes, and leads to an inhibition of cell growth in susceptible tumors. Also a potent inhibitor of MYC and the TMPRSS2-ETS fusion proteins.
CAS:
1445993-26-9
Formula:
C22H19F2N3O4S
Molecular Weight:
459.47
Pathway:
Apoptosis; Chromatin/Epigenetic
Purity:
0.9874
SMILES:
O=C1C=2NC=CC2C(=CN1C)C=3C=C(C=CC3OC4=CC=C(F)C=C4F)NS(=O)(=O)CC
Target:
Apoptosis; Epigenetic Reader Domain

References

Aparna Sarthy, et al. Experimental and Molecular Therapeutics. 2016, Abstract 4718.